guest ::
| Home > Publications database > Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C). > print |
| Home > Publications database > Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C). > print |
| 001 | 181165 | ||
| 005 | 20240229145642.0 | ||
| 024 | 7 | _ | |a 10.1016/j.cgh.2022.08.003 |2 doi |
| 024 | 7 | _ | |a pmid:35964896 |2 pmid |
| 024 | 7 | _ | |a 1542-3565 |2 ISSN |
| 024 | 7 | _ | |a 1542-7714 |2 ISSN |
| 024 | 7 | _ | |a altmetric:134088028 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01818 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Chen, Hongda |b 0 |
| 245 | _ | _ | |a Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C). |
| 260 | _ | _ | |a New York, NY |c 2023 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1677147683_6895 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 21, Issue 3, March 2023, Pages 808-818 |
| 520 | _ | _ | |a The screening yield and related cost of a risk-adapted screening approach compared with established screening strategies in population-based CRC screening are not clear.We randomly allocated 19,373 participants into one of the three screening arms in a 1:2:2 ratio: (1) one-time colonoscopy (n=3,883); (2) annual fecal immunochemical test (FIT) (n=7,793); (3) annual risk-adapted screening (n=7,697), in which, based on the risk-stratification score, high-risk participants were referred for colonoscopy, and low-risk ones were referred for FIT. Three consecutive screening rounds were conducted for both the FIT and the risk-adapted screening arms. Follow-up to trace the health outcome for all the participants was conducted over the 3-year study period. The detection rate of advanced colorectal neoplasia (CRC and advanced precancerous lesions) was the main outcome. The trial was registered in the Chinese Clinical Trial Registry (number: ChiCTR1800015506).In the colonoscopy, FIT, and risk-adapted screening arms over three screening rounds, the participation rates were 42.4%, 99.3%, and 89.2%, respectively; the detection rates for advanced neoplasm (intention-to-treat analysis) were 2.76%, 2.17%, and 2.35%, respectively, with odds ratio (OR)colonoscopyvs.FIT of 1.27 (95% confidence interval [CI]: 0.99-1.63; P=0.056), ORcolonoscopyvs.risk-adapted screening of 1.17 (95% CI: 0.91-1.49; P=0.218), and ORrisk-adapted screeningvs.FIT of 1.09 (95% CI: 0.88-1.35; P=0.438); the numbers of colonoscopies needed to detect one advanced neoplasm were 15.4, 7.8, and 10.2, respectively; the costs for detecting one advanced neoplasm from a government perspective using package payment format were CNY6,928 ($1,004), CNY5,821 ($844), and CNY6,694 ($970), respectively.The risk-adapted approach is a feasible and cost-favorable strategy for population-based CRC screening, and therefore could complement the well-established one-time colonoscopy and annual repeated FIT screening strategies. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a colonoscopy |2 Other |
| 650 | _ | 7 | |a colorectal cancer screening |2 Other |
| 650 | _ | 7 | |a fecal immunochemical test |2 Other |
| 650 | _ | 7 | |a personalized screening |2 Other |
| 650 | _ | 7 | |a risk stratification |2 Other |
| 700 | 1 | _ | |a Shi, Jufang |b 1 |
| 700 | 1 | _ | |a Lu, Ming |b 2 |
| 700 | 1 | _ | |a Li, Yanjie |b 3 |
| 700 | 1 | _ | |a Du, Lingbin |b 4 |
| 700 | 1 | _ | |a Liao, Xianzhen |b 5 |
| 700 | 1 | _ | |a Wei, Donghua |b 6 |
| 700 | 1 | _ | |a Dong, Dong |b 7 |
| 700 | 1 | _ | |a Gao, Yi |b 8 |
| 700 | 1 | _ | |a Zhu, Chen |b 9 |
| 700 | 1 | _ | |a Ying, Rongbiao |b 10 |
| 700 | 1 | _ | |a Zheng, Weifang |b 11 |
| 700 | 1 | _ | |a Yan, Shipeng |b 12 |
| 700 | 1 | _ | |a Xiao, Haifan |b 13 |
| 700 | 1 | _ | |a Zhang, Juan |b 14 |
| 700 | 1 | _ | |a Kong, Yunxin |b 15 |
| 700 | 1 | _ | |a Li, Furong |b 16 |
| 700 | 1 | _ | |a Zou, Shuangmei |b 17 |
| 700 | 1 | _ | |a Liu, Chengcheng |b 18 |
| 700 | 1 | _ | |a Wang, Hong |b 19 |
| 700 | 1 | _ | |a Zhang, Yuhan |b 20 |
| 700 | 1 | _ | |a Lu, Bin |b 21 |
| 700 | 1 | _ | |a Luo, Chenyu |b 22 |
| 700 | 1 | _ | |a Cai, Jie |b 23 |
| 700 | 1 | _ | |a Tian, Jianbo |b 24 |
| 700 | 1 | _ | |a Miao, Xiaoping |b 25 |
| 700 | 1 | _ | |a Ding, Kefeng |b 26 |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 27 |u dkfz |
| 700 | 1 | _ | |a Dai, Min |b 28 |
| 773 | _ | _ | |a 10.1016/j.cgh.2022.08.003 |g p. S1542356522007674 |0 PERI:(DE-600)2102638-5 |n 3 |p 808-818 |t Clinical gastroenterology and hepatology |v 21 |y 2023 |x 1542-3565 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:181165 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-27 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN GASTROENTEROL H : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-25 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b CLIN GASTROENTEROL H : 2022 |d 2023-10-25 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|